Here are the 10-Q quarterly reports from First Tracks Biotherapeutics, Inc. (TRAXV) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TRAXV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAXV filings page.
First Tracks Biotherapeutics reported a net loss of $50.5M for the three months ended March 31, 2026, driven by operating expenses of $52.8M. Research and development totaled $34.0M, down from 2025, while general and administrative expenses rose to $18.9M as the company scales as a standalone entity.
Cash, cash equivalents and short-term investments were $286.5M as of March 31, 2026, with $32.6M used in operating activities during the quarter. Management believes current resources will fund operations for at least 12 months. After quarter-end, the Spin-Off from AnaptysBio closed, the stock began trading on Nasdaq under “TRAX,” the company received $100M of cash in the separation and raised roughly $80M in gross proceeds via a private placement of 5.79M primary shares at $13.81 per share.